DNA test shows promise for noninvasive colorectal cancer detection

| | Health Imaging | Oncology Imaging

Exact Sciences has developed a stool-based screening test that detected 92 percent of cancers found on colonoscopy and 42 percent of precancerous polyps. The results fell shy of the company’s goal of a 50 percent polyp detection rate, according to an article in the New York Times; however, Exact Sciences indicated it plans to file for FDA approval of its Cologuard test.

Noninvasive Cancer Test Is Effective, Study Finds

Related Content

MRI-first approach could allow many to safely forego prostate biopsy
MRI guidance significantly reduces radiotherapy side effects compared to CT
Interventional procedure often as effective as surgery for difficult-to-treat liver cancer
AI tumor volume estimations could improve prostate cancer treatment strategies
MRI could be 'powerful tool' for guiding surgery decisions in patients with rectal cancer
Breast cancer only visible via MRI is often less aggressive

Around the web

Cardiovascular Business
Cardiology, radiology specialists debate CCTA’s rise as a go-to imaging modality for CAD

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.